During the corresponding time, Femasys Inc saw a revenue deteriorated by -18.92 % year on year, sequentially revenue fell by -21.9 %. While revenue at the Femasys Inc 's corporate clients
Femasys Inc's Comment on Sales, Marketing and Customers
The company provides infertility products, including FemSperm, FemBloc, FemCerv, and FemaSeed, targeting gynecologists and reproductive endocrinologists, particularly in non-covered states and high-volume areas. Its focus is on enabling gynecological practices to offer artificial insemination and in-office infertility procedures without requiring referrals to infertility specialists. The market includes gynecologists and advanced practice providers such as nurses and physician assistants. In the current market for permanent birth control, surgical tubal ligation is common but carries known risks and complications. As a result, some women choose temporary and reversible contraceptive methods like hormonal birth control and intrauterine devices (IUDs), despite their associated health risks and drawbacks.
In an exciting development within the healthcare sector, Femasys Inc., a recognized leader specializing in innovative women s healthcare solutions, has announced a groundbreaking partnership with Medical Electronic Systems to launch the FemSperm Analysis Kit. This strategic move not only expands the portfolio of Femasys products but also enhances the capabilities of gynecologists by providing a comprehensive in-office sperm handling solution tailored for the FemaSeed Intratubal Insemination procedure. Advancing In-Office Reproductive SolutionsThe introduction of the FemSperm Analysis Kit marks a significant step in empowering gynecologists with the tools they need to perform a complete assessment and handlin...
In today’s evolving healthcare landscape, women s health, particularly in reproductive medicine, has emerged as a focal point of innovation and investment. Femasys, Inc. a prominent player in this sector, has recently bolstered its standing through a forward-thinking partnership with the Carolinas Fertility Institute (CFI), one of America s premier fertility clinics. This collaboration aims to introduce FemaSeed, Femasys groundbreaking intratubal insemination product, to patients across more than eight CFI locations in North Carolina. Key Highlights of the PartnershipFemasys’ FemaSeed, which enables a more direct method of insemination, emerges as a first-line treatment option for infertility, a growing...
In a significant step forward for women’s reproductive health, Femasys, Inc. (Nasdaq: FEMY), a leading biomedical company headquartered in Atlanta, has announced the successful completion of its initial commercial FemaSeed infertility procedures in Europe. This breakthrough has led to the company receiving its second order from strategic distribution partners in Spain, highlighting the growing demand for innovative fertility solutions.Launched as a part of Femasys commitment to addressing the unmet needs of women globally, the FemaSeed treatment aims to enhance natural fertilization by delivering sperm directly into the fallopian tube the very site of conception. This innovative approach not only undersco...
Breaking Through: Femasys Secures CE Mark Approval for Women s Health Innovations When it comes to addressing the significant unmet needs in women s healthcare, Femasys Inc. stands at the forefront. The Atlanta-based biomedical company recently achieved a significant milestone by receiving European Union Medical Device Regulation (EU MDR) certification and CE Mark approval for four of its innovative products. These products, FemaSeed, FemVue, FemCerv, and FemCath, are now compliant with the stringent EU regulations, clearing the path for commercialization within Europe.It s an era of evolves, but women s health often lags in attention and innovation. Femasys is tackling this disparity head-on with a burgeoni...
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine Stanford Medicine, renowned for its long-standing dominance in gynecological research and groundbreaking innovations, has become the second academic center to participate in the FemBloc pivotal trial. The enrollment process for the trial commenced last quarter and has finally expanded its reach to include Stanford Medicine, further solidifying the importance of this trial in the field of women s healthcare. Femasys Inc., a leading medical device company specializing in women s health, is the driving force behind the FemBloc pivotal trial. Their ongoing commitment to revolutionizing gynecological healthcare has propelled them to...
Femasys Inc’s Comment on Sales, Marketing and Customers
The company provides infertility products, including FemSperm, FemBloc, FemCerv, and FemaSeed, targeting gynecologists and reproductive endocrinologists, particularly in non-covered states and high-volume areas. Its focus is on enabling gynecological practices to offer artificial insemination and in-office infertility procedures without requiring referrals to infertility specialists. The market includes gynecologists and advanced practice providers such as nurses and physician assistants. In the current market for permanent birth control, surgical tubal ligation is common but carries known risks and complications. As a result, some women choose temporary and reversible contraceptive methods like hormonal birth control and intrauterine devices (IUDs), despite their associated health risks and drawbacks.
Sources:
Femasys Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Femasys Inc’s corporate clients.
For your research, we’ve provided 9 tables on Femasys Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
208.43 %